Improving IVF Outcomes
Embryo selection remains a critical determinant of success in in vitro fertilization (IVF). Despite advances in assisted reproductive technologies, implantation rates per transferred embryo remain suboptimal, leading to repeated cycles, increased emotional burden, and higher healthcare costs.
Current embryo assessment methods rely primarily on morphological evaluation and, more recently, time-lapse imaging and AI-based pattern recognition. While these approaches have improved standardization, they do not directly capture the underlying biological and biomechanical properties of the embryo that may influence implantation potential.
There is growing recognition that embryo viability is multifactorial and that incorporating complementary, orthogonal biomarkers could meaningfully improve clinical decision-making and IVF outcomes.
Inventors
Prof. Iris Har Vardi, Soroka
Contact info
Sari Prutchi Sagiv PhD Director of Pharma and Diagnostics
For further information please contact:
sari@mor-research.comIVF clinics lack objective, biologically informative, and non-invasive biomarkers that directly reflect embryo quality and implantation competence. Existing methods are largely indirect, subjective, or dependent on complex imaging systems, and their predictive power remains limited.
Invasive testing options are not compatible with routine embryo transfer, while non-invasive approaches often provide incremental rather than transformative gains. As a result, clinicians frequently face uncertainty when selecting embryos for transfer, particularly in patients with repeated implantation failure or limited embryo availability.
There is a clear unmet need for a clinically actionable biomarker that can be seamlessly integrated into standard IVF workflows, improves implantation prediction, and does not compromise embryo integrity.
Mor Research has developed a patented, non-invasive biomechanical embryo biomarker that quantifies the shear modulus of the zona pellucida—an essential structural component of the embryo. The biomarker is derived from routine clinical procedures using advanced computational analysis, without altering standard laboratory workflows.
Preclinical and clinical studies demonstrate a statistically significant correlation between this biomechanical parameter and implantation outcomes, indicating its potential to serve as an independent and complementary predictor of embryo viability.
The technology is designed to integrate with existing embryo assessment platforms and decision-support tools, providing clinicians with an additional, objective data layer to support embryo selection and transfer decisions.
Over 2.5 million IVF cycles are performed annually worldwide, with continued market growth driven by delayed parenthood, increasing infertility prevalence, and broader access to assisted reproduction. Even modest improvements in implantation rates translate into significant clinical and economic value.
The solution is well positioned for licensing or integration with leading IVF equipment manufacturers, AI embryo assessment platforms, and fertility clinic networks. Its non-invasive nature and software-based implementation support scalable global adoption.
By enabling more accurate embryo selection and potentially reducing the number of required treatment cycles, this technology addresses a critical need in the IVF market and represents a compelling opportunity for strategic partners in reproductive medicine.